MedTrace Logo

Cardioprotection on Chemotherapy-Induced Cardiotoxicity

NCT06853951 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-03-03

No results posted yet for this study

Summary

The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.

Conditions

Interventions

DRUG

ACE Inhibitors

0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse.

DRUG

β -Blockers

0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Manal Hamed El-Hamamsy, Prof · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-18
Primary Completion
2025-03-30
Completion
2025-07-18

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06853951 on ClinicalTrials.gov